Authors : Rahul Punia; Dr. Arun Garg; Neha Bhamboo; Dr. Ashutosh Upadhayay

Volume/Issue : Volume 11 - 2026, Issue 4 - April

Google Scholar : https://tinyurl.com/2xertymt

Scribd : https://tinyurl.com/th8a5md7

DOI : https://doi.org/10.38124/ijisrt/26apr015

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Rheumatoid arthritis (RA) is a long-term autoimmune condition where the body’s immune system unwillingly attacks its own joints, leading to persistent inflammation, swelling (synovitis), and the gradual breakdown of joint tissues. At the heart of RA lies a complex interplay between immune cells especially B cells and T cells which release inflammatory messengers called cytokines. These molecules fuel the ongoing inflammation and contribute to joint damage over time. This review highlights how these immune cells drive the disease process and sustain tissue injury. In addition to conventional therapies, certain nutritional supplements like curcumin, guggul, and glucosamine–chondroitin blends offer mild relief. While not a replacement for standard treatments, they may serve as helpful add-ons in a broader management plan. Excitingly, nanotechnology is opening new frontiers in RA care. Unlike traditional drugs that circulate throughout the body, nanocarriers are engineered to deliver medication directly to inflamed joints. This targeted approach not only boosts treatment precision but also reduces unwanted side effects, offering a glimpse into the future of personalised RA therapy.

References :

1. Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol. 1998 May;27:S18–24.
2. Kalal B. “RHEUMATOID ARTHRITIS: CURRENT INSIGHT INTO PATHOGENESIS, DIAGNOSIS AND THERAPEUTIC ADVANCES.” J Popul Ther Clin Pharmacol. 2023 Apr 11;1–10.
3. Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA. 2018 Oct 2;320(13):1360.
4. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 2010 June;62(6):1576–82.
5. Gabriel SE. THE EPIDEMIOLOGY OF RHEUMATOID ARTHRITIS. Rheum Dis Clin N Am. 2001 May;27(2):269–81.
6. Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol [Internet]. 2022 Sept 6 [cited 2025 Oct 30]; Available from: https://www.nature.com/articles/s41584-022-00827-y
7. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology. 2012 July 1;51(suppl 5):v3–11.
8. Derksen VFAM, Huizinga TWJ, Van Der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol. 2017 June;39(4):437–46.
9. Mohanty S, Panda S, Bhanja A, Pal A, Chandra SS. Novel Drug Delivery Systems for Rheumatoid Arthritis: An Approach to Better Patient Compliance. Biomed Pharmacol J. 2019 Mar 28;12(1):157–70.
10. Kourilovitch M, Galarza-Maldonado C, Ortiz-Prado E. Diagnosis and classification of rheumatoid arthritis. J Autoimmun. 2014 Feb;48–49:26–30.
11. Dolati S, Sadreddini S, Rostamzadeh D, Ahmadi M, Jadidi-Niaragh F, Yousefi M. Utilization of nanoparticle technology in rheumatoid arthritis treatment. Biomed Pharmacother. 2016 May;80:30–41.
12. Liao KP, Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis. Curr Opin Rheumatol. 2009 May;21(3):279–83.
13. Paglia MDG, Silva MT, Lopes LC, Barberato-Filho S, Mazzei LG, Abe FC, et al. Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis. Florez ID, editor. PLOS ONE. 2021 Apr 7;16(4):e0248866.
14. Shtroblia V, Petakh P, Kamyshna I, Halabitska I, Kamyshnyi O. Recent advances in the management of knee osteoarthritis: a narrative review. Front Med. 2025 Jan 21;12:1523027.
15. Derry S, Conaghan P, Da Silva JAP, Wiffen PJ, Moore RA. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Pain, Palliative and Supportive Care Group, editor. Cochrane Database Syst Rev [Internet]. 2016 Apr 22 [cited 2025 Nov 1];2020(2). Available from: http://doi.wiley.com/10.1002/14651858.CD007400.pub3
16. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011 Oct;107(4):490–502.
17. Altman RD, Aven A, Holmburg CE, Pfeifer LM, Sack M, Young GT. Capsaicin cream 0.025% as Monotherapy for Osteoarthritis: A double-blind study. Semin Arthritis Rheum. 1994 June;23(6):25–33.
18. Moore RA, Derry S, McQuay HJ, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2011 [cited 2025 Nov 5]. p. CD008659.pub2. Available from: https://doi.wiley.com/10.1002/14651858.CD008659.pub2
19. Machado GC, Maher CG, Ferreira PH, Pinheiro MB, Lin CWC, Day RO, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015 Mar 31;350(mar31 2):h1225–h1225.
20. Da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, et al. RETRACTED: Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. The Lancet. 2016 May;387(10033):2093–105.
21. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res. 2020 Feb;72(2):149–62.
22. Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec;49(3):337–50.
23. Sohail R, Mathew M, Patel KK, Reddy SA, Haider Z, Naria M, et al. Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Gastroprotective NSAIDs on the Gastrointestinal Tract: A Narrative Review. Cureus [Internet]. 2023 Apr 3 [cited 2025 Nov 3]; Available from: https://www.cureus.com/articles/146797-effects-of-non-steroidal-anti-inflammatory-drugs-nsaids-and-gastroprotective-nsaids-on-the-gastrointestinal-tract-a-narrative-review
24. Sabha M, Hochberg MC. Non-surgical management of hip and knee osteoarthritis; comparison of ACR/AF and OARSI 2019 and VA/DoD 2020 guidelines. Osteoarthr Cartil Open. 2022 Mar;4(1):100232.
25. Jüni P, Hari R, Rutjes AW, Fischer R, Silletta MG, Reichenbach S, et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Musculoskeletal Group, editor. Cochrane Database Syst Rev [Internet]. 2015 Oct 22 [cited 2025 Nov 3];2015(11). Available from: http://doi.wiley.com/10.1002/14651858.CD005328.pub3
26. Gato-Calvo L, Magalhaes J, Ruiz-Romero C, Blanco FJ, Burguera EF. Platelet-rich plasma in osteoarthritis treatment: review of current evidence. Ther Adv Chronic Dis. 2019 Jan;10:2040622319825567.
27. Bennell KL, Paterson KL, Metcalf BR, Duong V, Eyles J, Kasza J, et al. Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA. 2021 Nov 23;326(20):2021.
28. Sconza C, Leonardi G, Carfì C, Kon E, Respizzi S, Scaturro D, et al. Intra-Articular Injection of Botulinum Toxin for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials. Int J Mol Sci. 2023 Jan 12;24(2):1486.
29. Mendes JG, Natour J, Nunes-Tamashiro JC, Toffolo SR, Rosenfeld A, Furtado RNV. Comparison between intra-articular Botulinum toxin type A, corticosteroid, and saline in knee osteoarthritis: a randomized controlled trial. Clin Rehabil. 2019 June;33(6):1015–26.
30. Singh JA, Mahowald ML, Noorbaloochi S. Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial. J Rheumatol. 2010 Nov;37(11):2377–86.
31. Arendt-Nielsen L, Jiang GL, DeGryse R, Turkel C. Intra-articular onabotulinumtoxinA in osteoarthritis knee pain: effect on human mechanistic pain biomarkers and clinical pain. Scand J Rheumatol. 2017 July 4;46(4):303–16.
32. Hill CL, March LM, Aitken D, Lester SE, Battersby R, Hynes K, et al. Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose. Ann Rheum Dis. 2016 Jan;75(1):23–9.
33. Ammon H, Wahl M. Pharmacology of Curcuma longa. Planta Med. 1991 Feb;57(01):1–7.
34. Gao Y, Zhuang Z, Lu Y, Tao T, Zhou Y, Liu G, et al. Curcumin Mitigates Neuro-Inflammation by Modulating Microglia Polarization Through Inhibiting TLR4 Axis Signaling Pathway Following Experimental Subarachnoid Hemorrhage. Front Neurosci. 2019 Nov 15;13:1223.
35. Kahkhaie KR, Mirhosseini A, Aliabadi A, Mohammadi A, Mousavi MJ, Haftcheshmeh SM, et al. Curcumin: a modulator of inflammatory signaling pathways in the immune system. Inflammopharmacology. 2019 Oct;27(5):885–900.
36. Yousefian M, Shakour N, Hosseinzadeh H, Hayes AW, Hadizadeh F, Karimi G. The natural phenolic compounds as modulators of NADPH oxidases in hypertension. Phytomedicine. 2019 Mar;55:200–13.
37. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. The Lancet. 2011 June;377(9783):2115–26.
38. Zhang Z, Leong DJ, Xu L, He Z, Wang A, Navati M, et al. Curcumin slows osteoarthritis progression and relieves osteoarthritis-associated pain symptoms in a post-traumatic osteoarthritis mouse model. Arthritis Res Ther. 2016 Dec;18(1):128.
39. Yan D, He B, Guo J, Li S, Wang J. Involvement of TLR4 in the protective effect of intra-articular administration of curcumin on rat experimental osteoarthritis. Acta Cir Bras. 2019;34(6):e201900604.
40. Chen B, Li H, Ou G, Ren L, Yang X, Zeng M. Curcumin attenuates MSU crystal-induced inflammation by inhibiting the degradation of IκBα and blocking mitochondrial damage. Arthritis Res Ther. 2019 Dec;21(1):193.
41. Li X, Xu D, Sun D, Zhang T, He X, Xiao D. Curcumin ameliorates monosodium urate‐induced gouty arthritis through Nod‐like receptor 3 inflammasome mediation via inhibiting nuclear factor‐kappa B signaling. J Cell Biochem. 2019 Apr;120(4):6718–28.
42. Deng R. Therapeutic Effects of Guggul and Its Constituent Guggulsterone: Cardiovascular Benefits. Cardiovasc Drug Rev. 2007 Dec;25(4):375–90.
43. Shishodia S, Sethi G, Ahn KS, Aggarwal BB. Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. Biochem Pharmacol. 2007 June;74(1):118–30.
44. Hazra AK, Sur TK, Chakraborty B, Seal T. HPLC ANALYSIS OF PHENOLIC ACIDS AND ANTIOXIDANT ACTIVITY OF SOME CLASSICAL AYURVEDIC GUGGULU FORMULATIONS. Int J Res Ayurved Pharm. 2018 Jan 21;9(1):112–7.
45. Shishodia S, Aggarwal BB. Guggulsterone Inhibits NF-κB and IκBα Kinase Activation, Suppresses Expression of Anti-apoptotic Gene Products, and Enhances Apoptosis. J Biol Chem. 2004 Nov;279(45):47148–58.
46. Gujral ML, Sareen K, Tangri KK, Amma MK, Roy AK. Antiarthritic and anti-inflammatory activity of gum guggul (Balsamodendron mukul Hook). Indian J Physiol Pharmacol. 1960 Oct;4:267–73.
47. Sharma JN, Sharma JN. Comparison of the anti-inflammatory activity of Commiphora mukul (an indigenous drug) with those of phenylbutazone and ibuprofen in experimental arthritis induced by mycobacterial adjuvant. Arzneimittelforschung. 1977 July;27(7):1455–7.
48. Eriksen P, Bartels EM, Altman RD, Bliddal H, Juhl C, Christensen R. Risk of Bias and Brand Explain the Observed Inconsistency in Trials on Glucosamine for Symptomatic Relief of Osteoarthritis: A Meta‐Analysis of Placebo‐Controlled Trials. Arthritis Care Res. 2014 Dec;66(12):1844–55.
49. Reginster JY, Dudler J, Blicharski T, Pavelka K. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017 Sept;76(9):1537–43.
50. Reichenbach S, Sterchi R, Scherer M, Trelle S, Bürgi E, Bürgi U, et al. Meta-analysis: Chondroitin for Osteoarthritis of the Knee or Hip. Ann Intern Med. 2007 Apr 17;146(8):580–90.
51. Clegg DO, Reda DJ, Harris CL, Klein MA, O’Dell JR, Hooper MM, et al. Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. N Engl J Med. 2006 Feb 23;354(8):795–808.
52. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016 Oct;33(10):2373–87.
53. Lu W, Yao J, Zhu X, Qi Y. Nanomedicines: Redefining traditional medicine. Biomed Pharmacother. 2021 Feb;134:111103.
54. Soininen SK, Repo JK, Karttunen V, Auriola S, Vähäkangas KH, Ruponen M. Human placental cell and tissue uptake of doxorubicin and its liposomal formulations. Toxicol Lett. 2015 Dec;239(2):108–14.
55. Barenholz Y (Chezy). Doxil® — The first FDA-approved nano-drug: Lessons learned. J Controlled Release. 2012 June;160(2):117–34.
56. Komano Y, Yagi N, Onoue I, Kaneko K, Miyasaka N, Nanki T. Arthritic Joint-Targeting Small Interfering RNA-Encapsulated Liposome: Implication for Treatment Strategy for Rheumatoid Arthritis. J Pharmacol Exp Ther. 2012 Jan;340(1):109–13.
57. Kofoed Andersen C, Khatri S, Hansen J, Slott S, Pavan Parvathaneni R, Mendes AC, et al. Carbon Nanotubes—Potent Carriers for Targeted Drug Delivery in Rheumatoid Arthritis. Pharmaceutics. 2021 Mar 27;13(4):453.
58. Lee MJ, Lee MH, Shim CK. Inverse targeting of drugs to reticuloendothelial system-rich organs by lipid microemulsion emulsified with poloxamer 338. Int J Pharm. 1995 Jan;113(2):175–87.
59. Sun H, Zhan M, Mignani S, Shcharbin D, Majoral JP, Rodrigues J, et al. Modulation of Macrophages Using Nanoformulations with Curcumin to Treat Inflammatory Diseases: A Concise Review. Pharmaceutics. 2022 Oct 20;14(10):2239.
60. Kajal, Sharma DR, Pandit V, Ashawat M. Formulation and Evaluation of Niosomal Loaded Transdermal Patches for the Treatment of Osteoarthritis. Drug Deliv Lett. 2024 Sept;14(4):290–307.
61. Alotaibi BS, Waqas MK, Saleem S, Yasin H, Kharaba Z, Murtaza G. Rheumatoid Arthritis Treatment Potential of Stearic Acid Nanoparticles of Quercetin in Rats. ACS Omega. 2024 Feb 13;9(6):7003–11.
62. Sahu A, Rathee S, Saraf S, Raikwar S, Das Bidla P, Pawar RS, et al. Development and Characterization of Leflunomide and Resveratrol Loaded Nanostructured Lipid Carrier Based In-situ Hydrogel System for Effective Management of Rheumatoid Arthritis. J Pharm Innov. 2025 June;20(3):107.
63. Alenazi F, Moursi S, Mahmoud MR, Shahid SMA, Khatoon F, Shahid Khan M, et al. Withaferin A alleviates inflammation in animal models of arthritis by inhibiting the NF-κB pathway and cytokine release. Chem Biol Interact. 2024 Aug;398:111114.
64. Chando A, Basudkar V, Gharat S, Momin M, Khan T. Development and preclinical assessment of nanoemulgel loaded with phytoconstituents for the management of rheumatoid arthritis. Drug Deliv Transl Res. 2024 Feb;14(2):524–41.
65. Gad HA, Abbas H, El Sayed NS, Khattab MA, El Hassab MA, Mansour M. Berberine loaded thermosensitive lipid nanoparticles: in vitro characterization, in silico study, and in vivo anti-arthritic effect. J Liposome Res. 2024 Apr 2;34(2):303–15.
66. Bawazeer S, Khan I, Rauf A, Aljohani ASM, Alhumaydhi FA, Khalil AA, et al. Black pepper ( Piper nigrum ) fruit-based gold nanoparticles (BP-AuNPs): Synthesis, characterization, biological activities, and catalytic applications – A green approach. Green Process Synth. 2022 Jan 4;11(1):11–28.
67. Nabizadeh Z, Nasrollahzadeh M, Kruppke B, Nasrabadi D. A combination of chitosan nanoparticles loaded with celecoxib and kartogenin has anti-inflammatory and chondroprotective effects: Results from an in vitro model of osteoarthritis. Heliyon. 2024 May;10(10):e31058.
68. Nahata A, Seng LS. Terpenes and Terpene Based Nanoformulations: A New Prospect for Arthritis Management. Int J Med Pharm Health Sci. 2024 Dec 30;1(4):196–207.
69. Dhule KD, Nandgude TD. Lipid Nano-System Based Topical Drug Delivery for Management of Rheumatoid Arthritis: An Overview. Adv Pharm Bull. 2023 Nov 1;13(4):663–77.
70. Mohd Nordin UU, Ahmad N, Salim N, Mohd Yusof NS. Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects. RSC Adv. 2021;11(46):29080–101.
71. Tayeb HH, Felimban R, Almaghrabi S, Hasaballah N. Nanoemulsions: Formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks. Colloid Interface Sci Commun. 2021 Nov;45:100533.
72. Chuo SC, Mohd Setapar SH. Application of nanotechnology for development of cosmetics. In: Nanotechnology for the Preparation of Cosmetics Using Plant-Based Extracts [Internet]. Elsevier; 2022 [cited 2025 Nov 10]. p. 327–44. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780128229675000047
73. Müller R. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000 July 3;50(1):161–77.
74. Mohammed HA, Khan RA, Singh V, Yusuf M, Akhtar N, Sulaiman GM, et al. Solid lipid nanoparticles for targeted natural and synthetic drugs delivery in high-incidence cancers, and other diseases: Roles of preparation methods, lipid composition, transitional stability, and release profiles in nanocarriers’ development. Nanotechnol Rev. 2023 Feb 18;12(1):20220517.
75. Avasarala H, Dinakaran S, Boddeda B, Dasari SP, Jayanthi VR, Swaroopa P. Ethosomal gel: a novel choice for topical delivery of the antipsychotic drug Ziprasidone Hydrochloride. Braz J Pharm Sci. 2022;58:e19317.
76. Suresh P, Salem-Bekhit MM, Veedu HP, Alshehri S, Nair SC, Bukhari SI, et al. Development of a Novel Methotrexate-Loaded Nanoemulsion for Rheumatoid Arthritis Treatment with Site-Specific Targeting Subcutaneous Delivery. Nanomaterials. 2022 Apr 11;12(8):1299.
77. Srinivasan M, Rajabi M, A. Mousa S. Nanobiomaterials in cancer therapy. In: Nanobiomaterials in Cancer Therapy [Internet]. Elsevier; 2016 [cited 2025 Nov 10]. p. 57–89. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780323428637000037
78. Karim K, Mandal A, Biswas N, Guha A, Chatterjee S, Behera M, et al. Niosome: A future of targeted drug delivery systems. J Adv Pharm Technol Res. 2010;1(4):374.
79. Waddad AY, Abbad S, Yu F, Munyendo WLL, Wang J, Lv H, et al. Formulation, characterization and pharmacokinetics of Morin hydrate niosomes prepared from various non-ionic surfactants. Int J Pharm. 2013 Nov;456(2):446–58.
80. Fadaei MS, Fadaei MR, Kheirieh AE, Rahmanian-Devin P, Dabbaghi MM, Nazari Tavallaei K, et al. Niosome as a promising tool for increasing the effectiveness of anti-inflammatory compounds. EXCLI J 23Doc212 ISSN 1611-2156 [Internet]. 2024 [cited 2026 Jan 18]; Available from: https://www.excli.de/index.php/excli/article/view/6868
81. Mahmoud A, Rady M, Abdel-Halim M, El-Shenawy BM, Mansour S. Transdermal Delivery of Tofacitinib Citrate via Mannose-Decorated Transferosomes Loaded with Tofacitinib Citrate in Arthritic Joints. Mol Pharm. 2024 Dec 2;21(12):6458–72.
82. Jha S, K. Sharma P, Malviya R. Liposomal Drug Delivery System for Cancer Therapy: Advancement and Patents. Recent Pat Drug Deliv Formul. 2016 Dec 7;10(3):177–83.
83. Maja L, Željko K, Mateja P. Sustainable technologies for liposome preparation. J Supercrit Fluids. 2020 Nov;165:104984.
84. Temml V, Kutil Z. Structure-based molecular modeling in SAR analysis and lead optimization. Comput Struct Biotechnol J. 2021;19:1431–44.
85. Large DE, Abdelmessih RG, Fink EA, Auguste DT. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliv Rev. 2021 Sept;176:113851.
86. Pajewski R, Djedovič N, Harder E, Ferdani R, Schlesinger PH, Gokel GW. Pore formation in and enlargement of phospholipid liposomes by synthetic models of ceramides and sphingomyelin. Bioorg Med Chem. 2005 Jan;13(1):29–37.
87. Liu P, Chen G, Zhang J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules. 2022 Feb 17;27(4):1372.
88. Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif Cells Nanomedicine Biotechnol. 2016 Jan 2;44(1):381–91.
89. Cevc G, Gebauer D. Hydration-Driven Transport of Deformable Lipid Vesicles through Fine Pores and the Skin Barrier. Biophys J. 2003 Feb;84(2):1010–24.
90. Zheng X, Yang H, Zhang Z, Liang X, Liu Y, Wang C, et al. pH-responsive size-adjustable liposomes induce apoptosis of fibroblasts and macrophages for rheumatoid arthritis treatment. Acta Biomater. 2024 Apr;179:256–71.
91. Bendas ER, Tadros MI. Enhanced transdermal delivery of salbutamol sulfate via ethosomes. AAPS PharmSciTech. 2007 Oct;8(4):213.
92. Verma P, Pathak K. Therapeutic and cosmeceutical potential of ethosomes: An overview. J Adv Pharm Technol Res. 2010;1(3):274.
93. M. Abdulbaqi I, Darwis Y, Abdul Karim Khan N, Abou Assi R, Ali Khan A. Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials. Int J Nanomedicine. 2016 May;2279.
94. Shinde P, Page A, Bhattacharya S. Ethosomes and their monotonous effects on Skin cancer disruption. Front Nanotechnol. 2023 Jan 12;5:1087413.
95. Esposito E, Calderan L, Galvan A, Cappellozza E, Drechsler M, Mariani P, et al. Ex Vivo Evaluation of Ethosomes and Transethosomes Applied on Human Skin: A Comparative Study. Int J Mol Sci. 2022 Dec 1;23(23):15112.
96. Avasarala H, Dinakaran S, Boddeda B, Dasari SP, Jayanthi VR, Swaroopa P. Ethosomal gel: a novel choice for topical delivery of the antipsychotic drug Ziprasidone Hydrochloride. Braz J Pharm Sci. 2022;58:e19317.
97. Sguizzato M, Mariani P, Spinozzi F, Benedusi M, Cervellati F, Cortesi R, et al. Ethosomes for Coenzyme Q10 Cutaneous Administration: From Design to 3D Skin Tissue Evaluation. Antioxidants. 2020 June 3;9(6):485.
98. Fan C, Li X, Zhou Y, Zhao Y, Ma S, Li W, et al. Enhanced Topical Delivery of Tetrandrine by Ethosomes for Treatment of Arthritis. BioMed Res Int. 2013;2013:1–13.
99. Narkhede MR, Bhamare SN. Nanotechnology-Driven Drug Delivery in Rheumatoid Arthritis: Current Trends, Key Challenges, and Future Perspectives. Biosci Biotechnol Res Asia. 2025 Mar 25;22(1):1–21.
100. Gupta N, Shaik AR, Chettupalli AK, Bukke SPN, Goruntla N. Nanomedicine for the management of rheumatoid arthritis: current status and prospective therapeutic approaches. Discov Med. 2025 Apr 28;2(1):111.
101. Ren S, Xu Y, Dong X, Mu Q, Chen X, Yu Y, et al. Nanotechnology-empowered combination therapy for rheumatoid arthritis: principles, strategies, and challenges. J Nanobiotechnology. 2024 July 22;22(1):431.
102. Priya S, Jain KK, Daryani J, Desai VM, Kathuria H, Singhvi G. Revolutionizing rheumatoid arthritis treatment with emerging cutaneous drug delivery systems: overcoming the challenges and paving the way forward. Nanoscale. 2025;17(1):65–87.